Skip to main content
Top
Published in: Supportive Care in Cancer 11/2006

01-11-2006 | Original Article

Symptom profiles and palliative care in advanced pancreatic cancer—a prospective study

Authors: Knut Jørgen Labori, Marianne Jensen Hjermstad, Torunn Wester, Trond Buanes, Jon Håvard Loge

Published in: Supportive Care in Cancer | Issue 11/2006

Login to get access

Abstract

Objectives

To describe prospectively the prevalence and severity of disease-related symptoms, quality of life (QOL) and need for palliative care in patients with advanced pancreatic cancer.

Patients and methods

Fifty-one patients treated for advanced pancreatic cancer filled in the Edmonton Symptom Assessment Scale (ESAS) for symptom registration and the EORTC QLQ-C30 and QLQ-PAN26 quality of life questionnaires at first contact (baseline) and the ESAS in the following consultations. Need for palliative interventions were registered.

Results

Of the 22 women and 29 men (mean age, 62 years), 20 had locally unresectable cancer, 19 had metastatic disease, and 12 had recurrent disease after curative resection. Forty-six patients died during follow-up (median survival, 99 days). At baseline, patients reported significantly impaired QOL on nine of 15 scales/items (p<0.01) relative to the general population. Fatigue, loss of appetite, and impaired sense of well-being were the most troublesome symptoms on the ESAS, measured to 4.4(±2.8)/5.3(±2.3), 4.4(±3.2)/5.9(±2.7), and 4.0(±2.9)/4.6(±2.7) (mean±SD) at baseline and 8 weeks before death, respectively. Forty-four of the 51 (86%) initial consultations and 107 (58%) of the 185 follow-ups (124 clinical and 61 phone-calls) resulted in palliative care interventions, most frequently changes in opioid or laxative medication and dietary advice.

Conclusions

Patients with advanced pancreatic cancer develop several distressing symptoms. ESAS was useful for assessment of symptom prevalence and intensity and is a clinically adequate method for symptom control. A multidisciplinary approach is necessary for the best palliation of symptoms at the time of diagnosis and during follow-up.
Literature
1.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A et al (1993) The European Organization for Research and Treatment of Cancer: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMed Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A et al (1993) The European Organization for Research and Treatment of Cancer: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMed
2.
go back to reference Bachmann P, Marti-Massoud C, Blanc-Vincent MP, Desport JC et al (2003) Summary version of the standards, options and recommendations for palliative or terminal nutrition in adults with progressive cancer (2001). Br J Cancer 89(Suppl 1):S107–S110CrossRefPubMed Bachmann P, Marti-Massoud C, Blanc-Vincent MP, Desport JC et al (2003) Summary version of the standards, options and recommendations for palliative or terminal nutrition in adults with progressive cancer (2001). Br J Cancer 89(Suppl 1):S107–S110CrossRefPubMed
3.
go back to reference Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6–9PubMed Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6–9PubMed
4.
go back to reference Chow E, Wong R, Connolly R, Hruby G, Franssen E, Fung KW et al (2001) Prospective assessment of symptom palliation for patients attending a rapid response radiotherapy program: feasibility of telephone follow-up. J Pain Symptom Manage 22:649–656CrossRefPubMed Chow E, Wong R, Connolly R, Hruby G, Franssen E, Fung KW et al (2001) Prospective assessment of symptom palliation for patients attending a rapid response radiotherapy program: feasibility of telephone follow-up. J Pain Symptom Manage 22:649–656CrossRefPubMed
5.
go back to reference Dormann A, Meisner S, Verin N, Wenk LA (2004) Self-expanding metal stents for gastroduodenal malignancies: systematic review of their clinical effectiveness. Endoscopy 36:543–550CrossRefPubMed Dormann A, Meisner S, Verin N, Wenk LA (2004) Self-expanding metal stents for gastroduodenal malignancies: systematic review of their clinical effectiveness. Endoscopy 36:543–550CrossRefPubMed
6.
go back to reference Fayers PM, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) EORTC QLQ-C30 scoring manual (3rd edn). EORTC Quality of Life Group, Brussels, Belgium Fayers PM, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) EORTC QLQ-C30 scoring manual (3rd edn). EORTC Quality of Life Group, Brussels, Belgium
7.
go back to reference Heedman PA, Strang P (2001) Symptom assessment in advanced palliative home care for cancer patients using the ESAS: clinical aspects. Anticancer Res 21:4077–4082PubMed Heedman PA, Strang P (2001) Symptom assessment in advanced palliative home care for cancer patients using the ESAS: clinical aspects. Anticancer Res 21:4077–4082PubMed
8.
go back to reference Fitzsimmons D, Johnson CD, George S, Payne S, Sandberg AA et al (1999) Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer 35:939–941CrossRefPubMed Fitzsimmons D, Johnson CD, George S, Payne S, Sandberg AA et al (1999) Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer 35:939–941CrossRefPubMed
9.
go back to reference Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S (1998) Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer core quality-of-life questionnaire: the QLQ=C30 (+3). J Clin Oncol 16:1188–1196PubMed Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S (1998) Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer core quality-of-life questionnaire: the QLQ=C30 (+3). J Clin Oncol 16:1188–1196PubMed
10.
go back to reference House MG, Choti MA (2004) Palliative therapy for pancreatic/biliary cancer. Surg Oncol Clin N Am 13:491–503,ixCrossRefPubMed House MG, Choti MA (2004) Palliative therapy for pancreatic/biliary cancer. Surg Oncol Clin N Am 13:491–503,ixCrossRefPubMed
11.
go back to reference Inui A (2002) Cancer anorexia–cachexia syndrome: current issues in research and management. CA Cancer J Clin 52:72–91PubMedCrossRef Inui A (2002) Cancer anorexia–cachexia syndrome: current issues in research and management. CA Cancer J Clin 52:72–91PubMedCrossRef
12.
go back to reference Jacox A, Carr DB, Payne R (1994) Management of cancer pain. Clinical practice guideline No. 9. AHCPR publication No. 94-0592. Rockville, MD. Agency for Health Care Policy and Research, U.S. Department of Health and Human Services, Public Health Service, March 1994, p. 19 Jacox A, Carr DB, Payne R (1994) Management of cancer pain. Clinical practice guideline No. 9. AHCPR publication No. 94-0592. Rockville, MD. Agency for Health Care Policy and Research, U.S. Department of Health and Human Services, Public Health Service, March 1994, p. 19
13.
go back to reference Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM et al (2004) Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer 101(1):3–27CrossRefPubMed Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM et al (2004) Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer 101(1):3–27CrossRefPubMed
14.
go back to reference Jordhoy MS, Kaasa S, Fayers P, Ovreness T, Underland G et al (1999) Challenges in palliative care research; recruitment, attrition and compliance: experience from a randomized controlled trial. Palliat Med 13:299–310CrossRefPubMed Jordhoy MS, Kaasa S, Fayers P, Ovreness T, Underland G et al (1999) Challenges in palliative care research; recruitment, attrition and compliance: experience from a randomized controlled trial. Palliat Med 13:299–310CrossRefPubMed
15.
go back to reference Lillemoe KD, Cameron JL, Hardacre JM, Sohn TA, Sauter PK et al (1999) Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg 230:322–328CrossRefPubMed Lillemoe KD, Cameron JL, Hardacre JM, Sohn TA, Sauter PK et al (1999) Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg 230:322–328CrossRefPubMed
16.
go back to reference Miaskowski C, Portenoy RK (1998) Update on the assessment and management of cancer-related fatigue. Princ Prac Support Oncol Updates 1(2):1–10 Miaskowski C, Portenoy RK (1998) Update on the assessment and management of cancer-related fatigue. Princ Prac Support Oncol Updates 1(2):1–10
17.
go back to reference Morris JN, Sherwood S (1987) Quality of life of cancer patients at different stages in the disease trajectory. J Chronic Dis 40:545–556CrossRefPubMed Morris JN, Sherwood S (1987) Quality of life of cancer patients at different stages in the disease trajectory. J Chronic Dis 40:545–556CrossRefPubMed
18.
go back to reference Morris JN, Suissa S, Sherwood S, Wright SM, Greer D (1986) Last days: a study of the quality of life of terminally ill cancer patients. J Chronic Dis 39:47–62CrossRefPubMed Morris JN, Suissa S, Sherwood S, Wright SM, Greer D (1986) Last days: a study of the quality of life of terminally ill cancer patients. J Chronic Dis 39:47–62CrossRefPubMed
19.
go back to reference Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200–1210CrossRefPubMed Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200–1210CrossRefPubMed
20.
go back to reference Nieveen van Dijkum EJ, Kuhlmann KF, Terwee CB, Obertop H et al (2005) Quality of life after curative or palliative surgical treatment of pancreatic and periampullary carcinoma. Br J Surg 92:471–477CrossRefPubMed Nieveen van Dijkum EJ, Kuhlmann KF, Terwee CB, Obertop H et al (2005) Quality of life after curative or palliative surgical treatment of pancreatic and periampullary carcinoma. Br J Surg 92:471–477CrossRefPubMed
21.
go back to reference Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144PubMed Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144PubMed
22.
go back to reference Rees E, Hardy J, Ling J, Broadley K, A’Hern R (1998) The use of the Edmonton Symptom Assessment Scale (ESAS) within a palliative care unit in the UK. Palliat Med 12:75–82CrossRefPubMed Rees E, Hardy J, Ling J, Broadley K, A’Hern R (1998) The use of the Edmonton Symptom Assessment Scale (ESAS) within a palliative care unit in the UK. Palliat Med 12:75–82CrossRefPubMed
23.
go back to reference Schmier J, Elixhauser A, Halpern MT (1999) Health-related quality of life evaluations of gastric and pancreatic cancer. Hepatogastroenterology 46:1998–2004PubMed Schmier J, Elixhauser A, Halpern MT (1999) Health-related quality of life evaluations of gastric and pancreatic cancer. Hepatogastroenterology 46:1998–2004PubMed
24.
go back to reference Singh SM, Longmire WP Jr, Reber HA (1990) Surgical palliation for pancreatic cancer. The UCLA experience. Ann Surg 212:132–139PubMedCrossRef Singh SM, Longmire WP Jr, Reber HA (1990) Surgical palliation for pancreatic cancer. The UCLA experience. Ann Surg 212:132–139PubMedCrossRef
25.
go back to reference Sohn TA, Lillemoe KD, Cameron JL, Huang JJ, Pitt HA, Yeo CJ (1999) Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. J Am Coll Surg 188:658–666CrossRefPubMed Sohn TA, Lillemoe KD, Cameron JL, Huang JJ, Pitt HA, Yeo CJ (1999) Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. J Am Coll Surg 188:658–666CrossRefPubMed
26.
go back to reference Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N (2000) Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer fatigue forum. Ann Oncol 11:971–975CrossRefPubMed Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N (2000) Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer fatigue forum. Ann Oncol 11:971–975CrossRefPubMed
27.
go back to reference van Geenen RC, van Gulik TM, Offerhaus GJ, de Wit LT, Busch OR et al (2001) Survival after pancreaticoduodenectomy for periampullary adenocarcinoma: an update. Eur J Surg Oncol 27:549–557CrossRefPubMed van Geenen RC, van Gulik TM, Offerhaus GJ, de Wit LT, Busch OR et al (2001) Survival after pancreaticoduodenectomy for periampullary adenocarcinoma: an update. Eur J Surg Oncol 27:549–557CrossRefPubMed
28.
go back to reference van Heek NT, De Castro SM, van Eijck CH, van Geenen RC et al (2003) The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer: a prospective randomized multicenter trial with special focus on assessment of quality of life. Ann Surg 238:894–902PubMed van Heek NT, De Castro SM, van Eijck CH, van Geenen RC et al (2003) The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer: a prospective randomized multicenter trial with special focus on assessment of quality of life. Ann Surg 238:894–902PubMed
29.
go back to reference Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F (1987) A validation study of the WHO method for cancer pain relief. Cancer 59:850–856PubMedCrossRef Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F (1987) A validation study of the WHO method for cancer pain relief. Cancer 59:850–856PubMedCrossRef
30.
go back to reference Wong GY, Schroeder DR, Carns PE, Wilson JL, Martin DP et al (2004) Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA 291:1092–1099CrossRefPubMed Wong GY, Schroeder DR, Carns PE, Wilson JL, Martin DP et al (2004) Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA 291:1092–1099CrossRefPubMed
31.
go back to reference Yeo CJ, Sohn TA, Cameron JL, Hruban RH, Lillemoe KD, Pitt HA (1998) Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg 227:821–831CrossRefPubMed Yeo CJ, Sohn TA, Cameron JL, Hruban RH, Lillemoe KD, Pitt HA (1998) Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg 227:821–831CrossRefPubMed
Metadata
Title
Symptom profiles and palliative care in advanced pancreatic cancer—a prospective study
Authors
Knut Jørgen Labori
Marianne Jensen Hjermstad
Torunn Wester
Trond Buanes
Jon Håvard Loge
Publication date
01-11-2006
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 11/2006
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-006-0067-0

Other articles of this Issue 11/2006

Supportive Care in Cancer 11/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine